IVI. V. Vasileva

I. V. Vasileva

*This is an algorithmically generated author record based on publicly available information.

I. V. Vasileva has a total of 192 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Obinutuzumab-Based Regimens in the First-Line Therapy for Follicular Lymphoma: Data from Real-World Clinical Practice in 41 Medical Institutions

    by Lali Galimovna Babicheva, G. S. Tumyan, I. V. Poddubnaya, G. V. Anisimova, O. Yu. Arzhanukhina, E. N. Babich, Yu. M. Bala, V. I. Bakhtina, O. V. Berezina, I. A. Bogomolova, et al.

    AIM. To assess the efficacy and safety of combined obinutuzumab-based regimens in the first-line therapy for follicular lymphoma (FL) in real-world clinical practice. MATERIALS & METHODS. This retrospective multicenter study enrolled 279 newly diagnosed FL patients treated with obinutuzumab in combination with chemotherapy at 41 medical institutions in Russia from 2018 to 2026. The median age of patients was 49.2 years (range 30–83 years), 60.6 % of them were women. Obinutuzumab-based regimens were predominantly administered to patients with stage III/IV (86.4 %), advanced tumor spread (60.2 %), and often with intraabdominal location (76.3 %). More than 1/3 of patients had extranodal lesions (41.9 %) and bulky tumors (34.8 %). According to FLIPI score, there were 74.9 % of patients with intermediate and poor prognosis. More than half of the patients (54.4 %) received anthracycline-based G-CHOP regimen as initial therapy, GB was administered to 30.1 % of patients. Maintenance therapy with obinutuzumab was used in 72.8 % of cases. RESULTS. Overall response to therapy was achieved in 95.6 % of patients, the rate of complete metabolic response was 91.1 %. Adverse events of any grade were observed in 51.8 % of patients, grade ≥ 3 was identified in 29 % (primarily neutropenia and infectious complications). With the median follow-up of 16.3 months, disease progression or relapse were diagnosed in 21 (7.5 %) patients, histological transformation into diffuse large B-cell lymphoma was reported after 6 out of 14 biopsies performed at the stage of FL relapse. The 2-year progression-free survival was 89.6 %, and the 2-year overall survival was 98 %. CONCLUSION. The results of this study confirm high efficacy of obinutuzumab in the first-line therapy for FL patients with prognostically unfavorable characteristics of tumor. Overall and complete metabolic response rates are consistent with the international data. The administration of obinutuzumab-based regimens provide significant therapeutic control of the disease and confirm the reproducibility of the data from clinical studies in real-world healthcare practice.

  • Open Access

    Real-World Outcomes of Glofitamab therapy in CAR-T naïve Patients with Relapsed/Refractory Large B-cell lymphoma

    by Liudmila Fedorova, Natalia Mikhailova, Kirill Lepik, Vladislav Markelov, Andrey Chekalov, Olesya Smykova, Gayane Tumyan, Anastasia Semenova, Arman Arakelyan, Lev Butaev, et al.

  • Open Access

    Efficacy and Safety of Glofitamab Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A United Russian Experience Based on the Compassionate Use Program

    by Liudmila Valerevna Fedorova, N. B. Mikhailova, K. V. Lepik, A. M. Chekalov, O. G. Smykova, V. V. Markelov, G. S. Tumyan, A. A. Semenova, A. V. Arakelyan, L. S. Butaev, et al.

    BACKGROUND. Clinical trials of glofitamab (Glofit) have demonstrated its high efficacy and tolerable toxicity profile in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients. However, the data on its use in a real-world setting remain sparse. AIM. To assess the efficacy and safety of Glofit in the combined cohort of R/R DLBCL patients in a real-world setting in the Russian Federation. MATERIALS & METHODS. This retrospective multi-center study enrolled 88 R/R DLBCL patients treated with Glofit under a compassionate use program from 2021 to 2024 in 22 Russian medical institutions. The median age of patients was 54 years (range 21–83 years), there were 42 (48 %) male patients. The main eligibility criteria were ≥ 3 prior therapy lines and exhaustion of available standard treatment methods. Glofit was administered as a monoregimen according to the schedule recommended in the package insert. RESULTS. With the follow-up median of 8.4 months (range 0.6–52 months), overall response was achieved in 46 (53 %) patients including 36 (42 %) patients with complete response (CR). The median overall survival (OS) was 13.1 months (95% confidence interval [95% CI] from 8.6 months to not reached), the 1-year OS was 55.7 % (95% CI 45.6–68.1 %). The median progression-free survival (PFS) was 4.2 months (95% CI 2.8–8.8 months), and the 1-year PFS was 33.5 % (95% CI 24.6–45.8 %). The median OS and PFS in patients with CR was not reached, whereas the 1-year PFS and OS were 73.7 % (95% CI 59.4–91.5 %) and 87.9 % (95% CI 77.4–99.9 %), respectively. Adverse events (AEs) were reported in 75 (85 %) patients, among them AEs of grade ≥ 3 in 35 (40 %) patients. Cytokine release syndrome was identified in 33 (38 %) patients, and “flare” syndrome was registered in 14 (16 %) patients. Infectious complications were observed in 45 (51 %) patients. Grade 5 AEs included only COVID-19 infection (n = 7; 8 %). Male gender, early relapse/refractoriness as well as 3-month administration of bendamustine prior to Glofit therapy were associated with the rate of achieving CR. PFS was lower in bendamustine recipients and also in cases with B-symptoms and massive tumor (bulky, > 7.5 cm). CONCLUSION. Glofit demonstrated high efficacy and tolerable toxicity profile in the treatment of R/R DLBCL patients. The results obtained in a real-world setting confirm the data from previously published clinical trials.

  • Open Access

    Treatment of Patients with Myelofibrosis and Polyscythemia Vera with Constitutional Symptoms in Routine Clinical Practice in the Russian Federation

    by A. L. Melikyan, I. N. Subortseva, S. M. Kulikov, Yu. A. Chabaeva, E. A. Gilyazitdinova, K. P. Novoselov, E. A. Knyazeva, A. S. Egorova, I. S. Stepochkin, E. V. Koroleva, et al.

    Introduction. In the Russian Federation, there is insufficient data on approaches to the treatment of polycythemia vera (PV) and myelofibrosis (MF). There is also a lack of information on the assessment of treatment effectiveness in routine clinical practice. Aim : to study treatment approaches for patients with MF (primary myelofibrosis (PMF), post-polycythemic myelofibrosis (PPMF), post-thrombocythemic myelofibrosis (PTMF)) and PV in routine clinical practice. Materials and methods. A multicenter, non-interventional, prospective observational study included 2005 patients from 49 centers: PV — 1019 (50.8 %), MF — 986 (49.2 %) patients. Gender, age, diagnosis, disease duration, mutation status of the JAK2 V617F gene, risk groups, and quality of life were analyzed. Results. The median age of patients with PV was 57 years, MF — 55 years. In one third of PV patients, a histological examination of the bone marrow trepan biopsy was not performed; in MF, trepanobiopsy was not conducted in less than 10 % of cases. When assessing the risk of thrombotic complications in PV, only 9.0 % of patients were classified as high-risk, yet thrombotic events were reported in 13.7 % of cases. According to the IPSS index, 39.8 % of MF patients were classified as intermediate-2 and high-risk, while 27.0 % were classified by the DIPSS index. In more than 80 % of cases, patients received hydroxycarabamide. 76.9 % of MF patients responded to ruxolitinib therapy for a period of 60 months, but only 30 MF patients received it as first-line therapy. Ruxolitinib was used as second-line therapy in 183 (18.6 %) MF patients and 54 (5.3 %) PV patients in the entire study group. Analysis of survival in over 2,000 patients allowed for the evaluation of overall survival (OS) and event-free survival (EFS), which are close to epidemiological estimates, indicating the persistent complexity of treating these patients. The proportion of MF patients with progressive disease was comparable to the proportion of patients who responded to therapy for all drugs except ruxolitinib. The use of ruxolitinib made it possible to achieve remission in most patients. Conclusion. The study characterized treatment outcomes and clinical-demographic features of patients with MPN. Discrepancies exist between real-world clinical practice and the diagnostic and therapeutic algorithms presented in the clinical guidelines.

  • Open Access

    Efficacy of IsaPomDex triplet therapy in double refractory multiple myeloma patients in real clinical practice in Russia

    by М. В. Соловьева, L. P. Mendeleeva, T. I. Pospelova, N. V. Skvortsova, S. V. Voloshin, A. D. Garifullin, A. S. Chuprakova, T. A. Mitina, I. S. Usankin, И. В. Васильева, et al.

    Background. Data from real-life clinical practice studies provide additional information on the efficacy of new antitumor therapy regimens, including in patients who meet exclusion criteria for clinical trials.Aim. To evaluate the Isaomex triplet efficacy in multiple myeloma patients in real clinical practice.Materials and methods. From 2021 to 2024, the retrospective study included 83 double refractory multiple myeloma patients from 26 centers aged 38 to 85 years (median 63), who received the Isaomex triplet. Glomerular filtration rate ˂ 60 mL/min was detected at the time of isatuximabbased triplet initiation in 18 % patients, 2 of whom were on program hemodialysis. The median of previous therapy lines was 2 (1–6). The median time from diagnosis to initiation of isatuximabbased triplet therapy was 47 months (5–203). Survival curves were constructed using the Kaplan–Meier method. Statistical analysis was performed using Statistica 10 program.Results. Isaomex triplet therapy resulted in overall and renal responses in 76 % and 61 % of cases, respectively. The median progression free survival was 13.5 months. In the group of patients who did not receive daratumumab at previous stages, the median progression free survival was significantly higher and was 28 months vs 8 months (p ˂ 0.05). Threeyear overall survival was 81 %. Discontinuation of isatuximab due to the development of adverse event was recorded in 2 cases (2 %). In the group of patients with bone plasmacytomas (n = 46), Isaomex therapy resulted in an overall response rate of 67 %; 12‑month progression free survival was 48 %, and 1‑year overall survival was 76 %.Conclusion. The results of the Isaomex triplet use in real clinical practice for the treatment of relapsed multiple myeloma showed data comparable to the ICARIA registration study on the frequency of achieving a response, duration of progression free survival and overall survival. The triplet efficiency was shown in comorbid patients, with advanced stages and those undergoing renal replacement therapy.